OrbiMed Capital GP VII LLC Insider Trading -- Recent SEC Form 4 Transactions
OrbiMed Capital GP VII LLC (CIK 1760648) reported 33 SEC Form 4 insider transactions across 6 companies over the past 18 months (most recent 2026-09-30). Recent activity: Buy ADRX (10.7M shares), Buy ADRX (2.0M shares), Buy ADRX (769,601 shares), Buy ADRX (564,187 shares), Buy ADRX (300,249 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-30 | ADARx Pharmaceuticals, Inc. (ADRX) | Director | Buy | 10.7M | $0 |
| 2026-09-30 | ADARx Pharmaceuticals, Inc. (ADRX) | Director | Buy | 2.0M | $0 |
| 2026-09-30 | ADARx Pharmaceuticals, Inc. (ADRX) | Director | Buy | 769,601 | $0 |
| 2026-09-30 | ADARx Pharmaceuticals, Inc. (ADRX) | Director | Buy | 564,187 | $0 |
| 2026-09-30 | ADARx Pharmaceuticals, Inc. (ADRX) | Director | Buy | 300,249 | $5.1M |
| 2026-09-30 | ADARx Pharmaceuticals, Inc. (ADRX) | Director | Buy | 7.1M | $0 |
| 2026-09-30 | ADARx Pharmaceuticals, Inc. (ADRX) | Director | Buy | 1.3M | $0 |
| 2026-09-30 | ADARx Pharmaceuticals, Inc. (ADRX) | Director | Buy | 513,067 | $0 |
| 2026-09-30 | ADARx Pharmaceuticals, Inc. (ADRX) | Director | Buy | 256,448 | $0 |
| 2026-09-30 | ADARx Pharmaceuticals, Inc. (ADRX) | Director | Buy | 61,516 | $1.0M |
| 2026-09-30 | ADARx Pharmaceuticals, Inc. (ADRX) | Director | Buy | 588,235 | $10.0M |
| 2026-09-23 | Electra Therapeutics, Inc. (ETRA) | Director | Buy | 1.1M | $0 |
| 2026-09-23 | Electra Therapeutics, Inc. (ETRA) | Director | Buy | 2.0M | $0 |
| 2026-09-23 | Electra Therapeutics, Inc. (ETRA) | Director | Buy | 1.7M | $0 |
| 2026-09-23 | Electra Therapeutics, Inc. (ETRA) | Director | Buy | 333,333 | $5.0M |
| 2026-09-23 | Electra Therapeutics, Inc. (ETRA) | Director | Buy | 758,279 | $0 |
| 2026-09-23 | Electra Therapeutics, Inc. (ETRA) | Director | Buy | 1.0M | $15.0M |
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 24,846 | $1.1M |
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 1,477 | $66,465 |
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 787,024 | $35.7M |
| 2026-06-24 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 46,776 | $2.1M |
| 2026-06-17 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 9,086 | $409,052 |
| 2026-06-17 | Enliven Therapeutics, Inc. (ELVN) | 10% Owner | Sell | 272,322 | $12.3M |
| 2026-06-01 | Q32 Bio Inc. (QTTB) | Director | Buy | 1.2M | $10.0M |
| 2026-06-01 | Q32 Bio Inc. (QTTB) | Director | Buy | 625,000 | $5.0M |
Source: SEC Form 4 filings · as of 2026-09-30